Common Cold
📧 Sign up to get email alerts when something new happens for Common Cold.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-12-04FDA Approved: BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE — Original Application (Dr. Reddy's Labratories Inc.)
FDA approved an original ANDA for a generic cough-and-cold medication containing brompheniramine maleate, pseudoephedrine hydrochloride, and…
-
FDA approval · 2018-11-30FDA Approved: DIPHENHYDRAMINE HYDROCHLORIDE — Supplemental Application (Armas Pharmaceuticals Inc.)
FDA approved a supplemental application for diphenhydramine hydrochloride from Armas Pharmaceuticals Inc.
-
FDA approval · 2018-11-16FDA Approved: ALLERGY AND SINUS RELIEF — Original Application (Kroger Company)
FDA approved Kroger's original application for an OTC allergy and sinus relief product containing cetirizine hydrochloride and pseudoephedri…
-
FDA approval · 2018-11-01FDA Approved: MUCUS RELIEF DM — Original Application (Dolgencorp, Inc. (DOLLAR GENERAL & REXALL))
FDA approved the original application for MUCUS RELIEF DM, a combination cough suppressant and expectorant (guaifenesin and dextromethorphan…
-
FDA approval · 2018-07-31FDA Approved: CLARITIN-D 24 HOUR — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for CLARITIN-D 24 HOUR (loratadine and pseudoephedrine sulfate) from Bayer HealthCare LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2018-07-18Clinical Trial Update: Echinaforce Junior Bioavailability Trial [Phase 4]
Phase 4 trial of Echinaforce Junior for the common cold was withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-07-09Clinical Trial Update: PEACe: Ivy, Thyme and Cisti Extract (Phytus) Efficacy in Acute Cough [Phase 4]
Phase 4 clinical trial update evaluating the efficacy of PEACe containing Ivy, Thyme and Cisti Extract (Phytus) for acute cough and associat…
-
CLINICAL_TRIALS trial_result · 2018-06-19Clinical Trial Update: To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold [Phase 2]
Phase 2 trial evaluating the efficacy and safety of 1146A nasal spray in adults with common cold has completed and results were posted.
-
CLINICAL_TRIALS research · 2018-06-19Clinical Trial Update: Study to Investigate the Effects of Hot Drinks on Nasal Airway Resistance and Symptoms of Common Cold [NA]
A Cardiff University trial investigated whether hot beverages influence nasal airway resistance and symptoms in people with the common cold …
-
FDA approval · 2018-06-08FDA Approved: PROMETHAZINE AND PHENYLEPHRINE HCL, AND CODEINE PHOSPHATE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for PROMETHAZINE AND PHENYLEPHRINE HCL, AND CODEINE PHOSPHATE by Amneal Pharmaceuticals LLC.
-
FDA approval · 2018-04-19FDA Approved: CLARINEX-D 12 HOUR — Supplemental Application (Organon LLC)
FDA has approved a supplemental application for CLARINEX-D 12 HOUR (desloratadine and pseudoephedrine sulfate) submitted by Organon LLC.
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: Probiotics in Prevention of Common Cold [NA]
A completed clinical trial evaluating probiotics for the prevention of the common cold.
-
CLINICAL_TRIALS withdrawal · 2018-03-12Clinical Trial Update: An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu [Phase 3]
A Phase 3 clinical trial evaluating Theraflu Day Powder for cold and flu was withdrawn, indicating the program was terminated prior to compl…
-
CLINICAL_TRIALS withdrawal · 2018-03-12Clinical Trial Update: An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu [Phase 3]
A Phase 3 trial evaluating Theraflu Night Powder as an oral solution for cold and flu has been withdrawn.
-
FDA approval · 2018-03-05FDA Approved: MUCUS DM — Original Application (HyVee Inc)
FDA approved HyVee Inc's MUCUS DM as an original-application generic product containing dextromethorphan hydrobromide and guaifenesin for te…
-
FDA approval · 2018-02-26FDA Approved: ADVIL ALLERGY AND CONGESTION RELIEF — Supplemental Application (Haleon US Holdings LLC)
FDA approves a supplemental application to market ADVIL ALLERGY AND CONGESTION RELIEF, a fixed-dose combination product containing chlorphen…
-
FDA approval · 2017-12-29FDA Approved: GUAIFENESIN AND PSEUDOEPHEDRINE HCL — Original Application (Dr. Reddys Laboratories Limited)
FDA approved an original ANDA for guaifenesin and pseudoephedrine hydrochloride tablets from Dr. Reddys Laboratories Limited, establishing a…
-
FDA approval · 2017-12-01FDA Approved: IBUPROFEN AND PSEUDOEPHEDRINE HCL — Original Application (Aurohealth LLC)
FDA approved Aurohealth LLC's ibuprofen and pseudoephedrine HCl combination as an Original Application. It is an over-the-counter product in…
-
CLINICAL_TRIALS trial_result · 2017-09-01Clinical Trial Update: Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine [Phase 3]
The document notes the completion of a Phase 3 placebo- and active-controlled trial evaluating aspirin plus pseudoephedrine for the common c…
-
FDA approval · 2017-08-29FDA Approved: PROMETHAZINE AND PHENYLEPHRINE HCL, AND CODEINE PHOSPHATE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for a generic combination product containing promethazine, phenylephrine, and codeine phosphate manu…
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: Micronutrient Supplementation and Incidence of Common Cold [NA]
A completed clinical trial evaluated whether micronutrient supplementation affects the incidence of the common cold.
-
FDA approval · 2017-07-13FDA Approved: MUCINEX DM MAXIMUM STRENGTH — Supplemental Application (RB Health (US) LLC)
FDA approved a supplemental application for Mucinex DM Maximum Strength (guaifenesin and dextromethorphan hydrobromide) by RB Health (US) LL…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o. [Phase 3]
A Phase 3 trial evaluated the efficacy and safety of Ingavirin for influenza and acute respiratory infections in adolescents; the study has …
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants [Phase 1]
This Phase 1 study assessed the local nasal tolerability and safety of the investigational agent 1146A in healthy adult participants and has…
-
CLINICAL_TRIALS trial_result · 2017-06-19Clinical Trial Update: Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o. [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of Ingavirin for treating influenza and acute respiratory viral infections in chil…